• Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 1,237.58%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$1.57
▼ -0.16 (-9.25%)

This chart shows the closing price for PAVM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PAVmed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PAVM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PAVM

Analyst Price Target is $21.00
▲ +1,237.58% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for PAVmed in the last 3 months. The average price target is $21.00, with a high forecast of $21.00 and a low forecast of $21.00. The average price target represents a 1,237.58% upside from the last price of $1.57.

This chart shows the closing price for PAVM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in PAVmed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/5/2022
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/5/2023
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2023
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2023
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2023
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/28/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024Lake Street CapitalUpgradeStrong-BuyLow
8/18/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$21.00Low
1/20/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral$60.00 ➝ $22.50Low
1/18/2023Lake Street CapitalLower TargetBuy$75.00 ➝ $22.50Low
11/24/2022Ascendiant Capital MarketsSet Target$123.75Low
8/17/2022Lake Street CapitalLower TargetBuy$105.00 ➝ $75.00Low
6/9/2022Ascendiant Capital MarketsLower Target$135.00High
5/17/2022Maxim GroupLower TargetNA$45.00Low
4/7/2022Maxim GroupLower Target$150.00 ➝ $60.00High
2/12/2022Cantor FitzgeraldReiterated RatingOverweightHigh
8/13/2021Maxim GroupReiterated RatingBuy$120.00High
7/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
6/4/2021Maxim GroupReiterated RatingBuy$120.00High
3/29/2021Cantor FitzgeraldInitiated CoverageOverweight$120.00High
2/22/2021Lake Street CapitalBoost TargetBuy$75.00 ➝ $135.00High
11/5/2020Ascendiant Capital MarketsInitiated CoverageBuy$75.00Medium
10/13/2020Lake Street CapitalInitiated CoverageBuy$75.00Medium
5/30/2020Maxim GroupReiterated RatingBuy$75.00Low
5/22/2020Maxim GroupReiterated RatingBuy$75.00N/A
4/17/2020Maxim GroupReiterated RatingBuy$75.00High
2/26/2020Maxim GroupReiterated RatingBuy$75.00High
11/22/2019Maxim GroupReiterated RatingBuy$45.00Low
8/16/2019Maxim GroupSet TargetBuy$45.00Low
(Data available from 5/28/2019 forward)

News Sentiment Rating

-0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
11/30/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/28/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/29/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/28/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
5/28/2024

Current Sentiment

  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
PAVmed logo
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Read More

Today's Range

Now: $1.57
Low: $1.57
High: $1.69

50 Day Range

MA: $2.01
Low: $1.57
High: $2.73

52 Week Range

Now: $1.57
Low: $1.57
High: $9.00

Volume

94,721 shs

Average Volume

65,098 shs

Market Capitalization

$14.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

Frequently Asked Questions

What sell-side analysts currently cover shares of PAVmed?

The following Wall Street sell-side analysts have issued research reports on PAVmed in the last twelve months: Cantor Fitzgerald, and Lake Street Capital.
View the latest analyst ratings for PAVM.

What is the current price target for PAVmed?

1 Wall Street analysts have set twelve-month price targets for PAVmed in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 1,237.6%. Cantor Fitzgerald has the highest price target set, predicting PAVM will reach $21.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $21.00 for PAVmed in the next year.
View the latest price targets for PAVM.

What is the current consensus analyst rating for PAVmed?

PAVmed currently has 1 hold rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PAVM will outperform the market and that investors should add to their positions of PAVmed.
View the latest ratings for PAVM.

What other companies compete with PAVmed?

How do I contact PAVmed's investor relations team?

PAVmed's physical mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company's listed phone number is (212) 949-4319 and its investor relations email address is [email protected]. The official website for PAVmed is www.pavmed.com. Learn More about contacing PAVmed investor relations.